445 related articles for article (PubMed ID: 27385790)
1. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
2. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
3. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Transplant Cell Ther; 2021 Dec; 27(12):991.e1-991.e9. PubMed ID: 34500124
[TBL] [Abstract][Full Text] [Related]
6. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
8. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
9. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
Hunter A; Padron E
Curr Hematol Malig Rep; 2021 Jun; 16(3):247-255. PubMed ID: 33660195
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
11. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
12. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
[TBL] [Abstract][Full Text] [Related]
13. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
14. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
[TBL] [Abstract][Full Text] [Related]
15. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Mei M; Pillai R; Kim S; Estrada-Merly N; Afkhami M; Yang L; Meng Z; Abid MB; Aljurf M; Bacher U; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Copelan E; Cutler C; DeFilipp Z; Diaz Perez MA; Farhadfar N; Freytes CO; Gadalla SM; Ganguly S; Gale RP; Gergis U; Grunwald MR; Hamilton BK; Hashmi S; Hildebrandt GC; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Patel SS; Rizzieri D; Seo S; Shah MV; Solh M; Verdonck LF; Vij R; Sobecks RM; Oran B; Scott BL; Saber W; Nakamura R
Haematologica; 2023 Jan; 108(1):150-160. PubMed ID: 35443559
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
Tang G; Zhang L; Fu B; Hu J; Lu X; Hu S; Patel A; Goswami M; Khoury JD; Garcia-Manero G; Medeiros LJ; Wang SA
Am J Hematol; 2014 Aug; 89(8):813-8. PubMed ID: 24782398
[TBL] [Abstract][Full Text] [Related]
19. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
Patnaik MM; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Knudson RA; Ketterling RP; Tefferi A; Solary E
Leukemia; 2014 Nov; 28(11):2206-12. PubMed ID: 24695057
[TBL] [Abstract][Full Text] [Related]
20. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
Patnaik MM; Vallapureddy R; Yalniz FF; Hanson CA; Ketterling RP; Lasho TL; Finke C; Al-Kali A; Gangat N; Tefferi A
Am J Hematol; 2018 Jan; 93(1):65-73. PubMed ID: 29023992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
